JPS4966816A - - Google Patents

Info

Publication number
JPS4966816A
JPS4966816A JP47107776A JP10777672A JPS4966816A JP S4966816 A JPS4966816 A JP S4966816A JP 47107776 A JP47107776 A JP 47107776A JP 10777672 A JP10777672 A JP 10777672A JP S4966816 A JPS4966816 A JP S4966816A
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP47107776A
Other languages
Japanese (ja)
Other versions
JPS5443570B2 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP10777672A priority Critical patent/JPS5443570B2/ja
Priority to FR7338282A priority patent/FR2204421B1/fr
Priority to DE19732353797 priority patent/DE2353797A1/de
Priority to GB5004773A priority patent/GB1450960A/en
Publication of JPS4966816A publication Critical patent/JPS4966816A/ja
Publication of JPS5443570B2 publication Critical patent/JPS5443570B2/ja
Expired legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP10777672A 1972-10-27 1972-10-27 Expired JPS5443570B2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP10777672A JPS5443570B2 (ko) 1972-10-27 1972-10-27
FR7338282A FR2204421B1 (ko) 1972-10-27 1973-10-26
DE19732353797 DE2353797A1 (de) 1972-10-27 1973-10-26 Stabilisierung von prostaglandinen
GB5004773A GB1450960A (en) 1972-10-27 1973-10-26 Stabilization of prostaglandins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10777672A JPS5443570B2 (ko) 1972-10-27 1972-10-27

Publications (2)

Publication Number Publication Date
JPS4966816A true JPS4966816A (ko) 1974-06-28
JPS5443570B2 JPS5443570B2 (ko) 1979-12-20

Family

ID=14467713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10777672A Expired JPS5443570B2 (ko) 1972-10-27 1972-10-27

Country Status (4)

Country Link
JP (1) JPS5443570B2 (ko)
DE (1) DE2353797A1 (ko)
FR (1) FR2204421B1 (ko)
GB (1) GB1450960A (ko)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS536416A (en) * 1976-07-01 1978-01-20 Emu Esu Shii Yuugen 55fluorouracli inclusion compound
JPS53133623A (en) * 1977-04-21 1978-11-21 Fujimoto Seiyaku Kk Medical preparation including antiicholine active medicine by cyclodextrin analogue
JPS59148760A (ja) * 1983-02-12 1984-08-25 バイエル・アクチエンゲゼルシヤフト プロスタグランジンの複合体
JPS62103018A (ja) * 1985-07-08 1987-05-13 Chugai Pharmaceut Co Ltd 安定なニコランジル製剤
WO2006075690A1 (ja) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. 安定な医薬組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU176217B (en) * 1978-11-20 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-chamomille inclusion complex and compositions containing thereof
EP0056065B1 (de) * 1981-01-10 1984-04-04 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. Stabilisierte, lokal anwendbare Prostaglandintabletten mit regulierter Auflösungsgeschwindigkeit und Verfahren zu der Herstellung
JPS5830032B2 (ja) * 1981-02-18 1983-06-27 呉羽化学工業株式会社 ビフイダス菌の増殖剤
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
HU196306B (en) * 1985-04-01 1988-11-28 Chinoin Gyogyszer Es Vegyeszet New dusting powders comprising bioactive material and process for preparing the same
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5684121A (en) * 1994-12-06 1997-11-04 Isp Investments Inc. N-vinyl lactam polymer containing tablets of low friability and high rate of dissolution

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3504019A (en) * 1967-02-20 1970-03-31 American Home Prod Prostaglandin purification process
JPS503362B1 (ko) * 1970-06-10 1975-02-04
US3644638A (en) * 1970-08-24 1972-02-22 American Home Prod Compositions and methods for relieving bronchial spasm with prostanoic acids and esters

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS536416A (en) * 1976-07-01 1978-01-20 Emu Esu Shii Yuugen 55fluorouracli inclusion compound
JPS5530794B2 (ko) * 1976-07-01 1980-08-13
JPS53133623A (en) * 1977-04-21 1978-11-21 Fujimoto Seiyaku Kk Medical preparation including antiicholine active medicine by cyclodextrin analogue
JPS59148760A (ja) * 1983-02-12 1984-08-25 バイエル・アクチエンゲゼルシヤフト プロスタグランジンの複合体
JPS62103018A (ja) * 1985-07-08 1987-05-13 Chugai Pharmaceut Co Ltd 安定なニコランジル製剤
JPH075464B2 (ja) * 1985-07-08 1995-01-25 中外製薬株式会社 安定なニコランジル製剤
WO2006075690A1 (ja) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. 安定な医薬組成物

Also Published As

Publication number Publication date
DE2353797A1 (de) 1974-05-09
JPS5443570B2 (ko) 1979-12-20
FR2204421B1 (ko) 1977-09-09
GB1450960A (en) 1976-09-29
FR2204421A1 (ko) 1974-05-24

Similar Documents

Publication Publication Date Title
FR2166365B1 (ko)
FR2204421B1 (ko)
FR2211379A1 (ko)
JPS4971787A (ko)
JPS5412016B2 (ko)
JPS4950407A (ko)
JPS5422048B2 (ko)
JPS4956382A (ko)
FR2166306B1 (ko)
JPS511245B2 (ko)
JPS535477B2 (ko)
JPS565733B2 (ko)
DE2245552B2 (ko)
JPS4941840A (ko)
JPS4886558U (ko)
CH579842A5 (ko)
BG17358A1 (ko)
BG18043A1 (ko)
SE7108483L (ko)
CH584939A5 (ko)
CH580060A5 (ko)
CH579917A5 (ko)
CH562125A5 (ko)
CH579692A5 (ko)
CH579068A5 (ko)